P1.11-01 Utility of Ctdna Monitoring During Surveillance in Surgically Resected NSCLC Patients

Serial monitoring of circulating tumor DNA (ctDNA) for detection of molecular residual disease (MRD) has shown potential in predicting cancer recurrence and personalizing drug therapy in various cancer types. However, its effectiveness in managing non-small cell lung cancer (NSCLC) is not fully understood.